Zeno Corporation

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for the treatment of various cancers. Originally founded as Zeno Pharmaceuticals, the company utilizes its proprietary Integrated Discovery Engine to identify and optimize candidates that target fundamental biological pathways in oncology. Its lead candidate, azenosertib (ZN-c3), is a potentially best-in-class WEE1 inhibitor currently being evaluated in late-stage clinical trials for uterine serous carcinoma and other solid tumors. The company's pipeline also includes inhibitors targeting the estrogen receptor and BCL-2, aiming to address significant unmet needs in both solid and hematologic malignancies.